Hyperion Therapeutics to Present at the Annual Stifel 2013 Healthcare Conference

Hyperion Therapeutics to Present at the Annual Stifel 2013 Healthcare
Conference

SOUTH SAN FRANCISCO, Calif., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Hyperion
Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to
present at the annual Stifel 2013 Healthcare Conference on Thursday, September
12 at 9:45 a.m. ET.

Jeffrey Farrow, Chief Financial Officer will provide a company overview. To
access the live webcast and subsequent archived recording, please visit
Hyperion's website at http://investors.hyperiontx.com/events.cfm.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company
committed to developing and delivering life-changing treatments for orphan
diseases and hepatology. The company's first commercial product, RAVICTI®
(glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is
currently being marketed in the United States. The company also owns and
markets BUPHENYL® (sodium phenylbutyrate) Tablets and Powder worldwide. For
more information, please visit www.hyperiontx.com.

CONTACT: Sylvia Wheeler, Investor Relations
         (650) 794-7834
         sylvia.wheeler@hyperiontx.com